These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3111089)

  • 1. Tri(n-butyl) phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives.
    Edwards CA; Piet MP; Chin S; Horowitz B
    Vox Sang; 1987; 52(1-2):53-9. PubMed ID: 3111089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sterilisation of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate.
    Prince AM; Horowitz B; Brotman B
    Lancet; 1986 Mar; 1(8483):706-10. PubMed ID: 2870224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations.
    Horowitz B; Wiebe ME; Lippin A; Stryker MH
    Transfusion; 1985; 25(6):516-22. PubMed ID: 3934801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation.
    Piët MP; Chin S; Prince AM; Brotman B; Cundell AM; Horowitz B
    Transfusion; 1990 Sep; 30(7):591-8. PubMed ID: 2402772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance of vaccinia virus to inactivation by solvent/detergent treatment of blood products.
    Roberts P
    Biologicals; 2000 Mar; 28(1):29-32. PubMed ID: 10799053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purification of fibroblast growth factor-2 from human placenta using tri(n-butyl)phosphate and sodium cholate.
    Wolff P; Tanaka AM; Chenker E; Cabrera-Crespo J; Raw I; Ho PL
    Biochimie; 1996; 78(3):190-4. PubMed ID: 8831950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivation of lipid-enveloped viruses in labile blood derivatives by unsaturated fatty acids.
    Horowitz B; Piët MP; Prince AM; Edwards CA; Lippin A; Walakovits LA
    Vox Sang; 1988; 54(1):14-20. PubMed ID: 2831669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virus removal or inactivation in hemoglobin solutions by ultrafiltration or detergent/solvent treatment.
    Bechtel MK; Bagdasarian A; Olson WP; Estep TN
    Biomater Artif Cells Artif Organs; 1988; 16(1-3):123-8. PubMed ID: 2846096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative determination of residual sodium-cholate in tri(N-butyl)phosphate/sodium-cholate treated factor VIII-preparations.
    Dengler T; Kellner S; Fürst G
    Vox Sang; 1989; 57(3):161-3. PubMed ID: 2515653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies.
    Dichtelmüller HO; Biesert L; Fabbrizzi F; Gajardo R; Gröner A; von Hoegen I; Jorquera JI; Kempf C; Kreil TR; Pifat D; Osheroff W; Poelsler G
    Transfusion; 2009 Sep; 49(9):1931-43. PubMed ID: 19497061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of manufacturing process parameters on virus inactivation by solvent-detergent treatment in a high-purity factor IX concentrate.
    Roberts PL; Dunkerley C
    Vox Sang; 2003 Apr; 84(3):170-5. PubMed ID: 12670365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative assays for evaluation of HTLV-III inactivation procedures: tri(N-butyl)phosphate:sodium cholate and beta-propiolactone.
    Prince AM; Horowitz B; Dichtelmueller H; Stephan W; Gallo RC
    Cancer Res; 1985 Sep; 45(9 Suppl):4592s-4594s. PubMed ID: 2410108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system.
    Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
    Vox Sang; 2006 Jul; 91(1):56-62. PubMed ID: 16756602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virus safety of solvent/detergent-treated antihaemophilic factor concentrate.
    Horowitz MS; Rooks C; Horowitz B; Hilgartner MW
    Lancet; 1988 Jul; 2(8604):186-9. PubMed ID: 2899662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral safety of solvent-detergent treated blood products.
    Horowitz B; Prince AM; Horowitz MS; Watklevicz C
    Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large-scale production and properties of a solvent-detergent-treated factor IX concentrate from human plasma.
    Michalski C; Bal F; Burnouf T; Goudemand M
    Vox Sang; 1988; 55(4):202-10. PubMed ID: 3265237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography.
    Burnouf T; Burnouf-Radosevich M; Huart JJ; Goudemand M
    Vox Sang; 1991; 60(1):8-15. PubMed ID: 1905084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virucidal short wavelength ultraviolet light treatment of plasma and factor VIII concentrate: protection of proteins by antioxidants.
    Chin S; Williams B; Gottlieb P; Margolis-Nunno H; Ben-Hur E; Hamman J; Jin R; Dubovi E; Horowitz B
    Blood; 1995 Dec; 86(11):4331-6. PubMed ID: 7492794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigations into the application of tri(n-butyl)phosphate/detergent mixtures to blood derivatives.
    Horowitz B
    Curr Stud Hematol Blood Transfus; 1989; (56):83-96. PubMed ID: 2642786
    [No Abstract]   [Full Text] [Related]  

  • 20. Virus inactivation in a factor VIII/VWF concentrate treated using a solvent/detergent procedure based on polysorbate 20.
    Roberts PL; Lloyd D; Marshall PJ
    Biologicals; 2009 Jan; 37(1):26-31. PubMed ID: 18848782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.